Eben Tessari Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Eben Tessari is CHIEF OPERATING OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 80,438 shares of KNSA, which is worth approximately $1.86 Million. The most recent transaction as insider was on Apr 08, 2024, when has been sold 2,726 shares (Class A Common Share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 80.4K

16.19% 3M change

35.18% 12M change

Total Value Held $1.86 Million

Eben Tessari Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 08 2024	BUY Exercise of conversion of derivative security	-	2,726 Added 2.1%	126,825 Class A Common Share
Apr 01 2024	SELL Payment of exercise price or tax liability	$10,263 $19.7 p/Share	521 Reduced 0.42%	124,099 Class A Common Share
Apr 01 2024	BUY Exercise of conversion of derivative security	-	1,773 Added 1.4%	124,620 Class A Common Share
Mar 01 2024	SELL Open market or private sale	$26,193 $22.03 p/Share	1,189 Reduced 0.96%	122,847 Class A Common Share
Mar 01 2024	BUY Exercise of conversion of derivative security	$1,043 $1.59 p/Share	656 Added 0.53%	124,036 Class A Common Share
Sep 02 2023	SELL Payment of exercise price or tax liability	$10,247 $17.76 p/Share	577 Reduced 0.47%	123,380 Class A Common Share
Sep 02 2023	BUY Exercise of conversion of derivative security	-	1,964 Added 1.56%	123,957 Class A Common Share
Sep 01 2023	SELL Payment of exercise price or tax liability	$14,225 $17.76 p/Share	801 Reduced 0.65%	121,993 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,727 Added 2.17%	122,794 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$8,578 $10.71 p/Share	801 Reduced 0.66%	120,067 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,727 Added 2.21%	120,868 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$9,741 $11.12 p/Share	876 Reduced 0.74%	118,141 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	2,982 Added 2.44%	119,017 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$6,612 $11.46 p/Share	577 Reduced 0.49%	116,035 Class A Common Share
Mar 16 2023	BUY Exercise of conversion of derivative security	-	1,964 Added 1.66%	116,612 Class A Common Share
Sep 02 2022	SELL Payment of exercise price or tax liability	$6,601 $11.44 p/Share	577 Reduced 0.5%	114,648 Class A Common Share
Sep 02 2022	BUY Exercise of conversion of derivative security	-	1,964 Added 1.68%	115,225 Class A Common Share
Jul 15 2022	BUY Grant, award, or other acquisition	$10,019 $9.56 p/Share	1,048 Added 0.92%	113,261 Class A Common Share
Mar 21 2022	SELL Payment of exercise price or tax liability	$16,042 $10.98 p/Share	1,461 Reduced 1.29%	112,213 Class A Common Share
Mar 21 2022	BUY Exercise of conversion of derivative security	-	4,611 Added 3.9%	113,674 Class A Common Share
Mar 16 2022	SELL Payment of exercise price or tax liability	$6,899 $10.13 p/Share	681 Reduced 0.62%	109,063 Class A Common Share
Mar 16 2022	BUY Exercise of conversion of derivative security	-	1,964 Added 1.76%	109,744 Class A Common Share
Jan 15 2022	BUY Grant, award, or other acquisition	$9,341 $9.63 p/Share	970 Added 0.89%	107,780 Class A Common Share
Jul 15 2021	BUY Grant, award, or other acquisition	$9,973 $11.49 p/Share	868 Added 0.81%	106,810 Class A Common Share

Eben Tessari

CHIEF OPERATING OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account